Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma
NCT03475186Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ramipril in cognitive impairment, sponsored by Wake Forest University Health Sciences. Started Mar 2019; status: completed.
02
Drugs
ramipril
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT03475186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475186.